Miguel
Alcoceba Sánchez
Investigador desde 2011
Hospital Clinic Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (20)
2023
-
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
Blood Advances
-
Unraveling the genetics of transformed splenic marginal zone lymphoma
Blood Advances, Vol. 7, Núm. 14, pp. 3695-3709
2022
-
Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation
British Journal of Haematology, Vol. 196, Núm. 1, pp. 146-155
-
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
Nature Medicine, Vol. 28, Núm. 8, pp. 1662-1671
-
Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma
British Journal of Haematology, Vol. 196, Núm. 3, pp. 589-598
2021
-
Anti-trbc1 antibody-based flow cytometric detection of t-cell clonality: Standardization of sample preparation and diagnostic implementation
Cancers, Vol. 13, Núm. 17
-
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma
European Journal of Cancer, Vol. 157, pp. 132-139
2020
-
Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)
British Journal of Haematology, Vol. 190, Núm. 6, pp. 854-863
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
-
STAT3 and STAT5B mutations in T/NK-cell chronic lymphoproliferative disorders of large granular lymphocytes (LGL): Association with disease features
Cancers, Vol. 12, Núm. 12, pp. 1-20
2019
-
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population
British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491
-
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
Haematologica, Vol. 104, Núm. 3, pp. 576-586
2018
-
Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia
Leukemia, Vol. 32, Núm. 3, pp. 645-653
-
Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets
Leukemia, Vol. 32, Núm. 3, pp. 675-684
-
Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series
Annals of Hematology, Vol. 97, Núm. 12, pp. 2417-2424
-
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
The Lancet Haematology, Vol. 5, Núm. 8, pp. e359-e367
-
The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia
Leukemia and Lymphoma, Vol. 59, Núm. 10, pp. 2318-2326
2017
-
A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma
Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106
-
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
British Journal of Haematology, Vol. 178, Núm. 5, pp. 699-708
2014
-
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
Leukemia, Vol. 28, Núm. 2, pp. 391-397